Virus-Enhanced cocktail takes on Hard-to-Treat myeloma
NCT ID NCT05514990
First seen Nov 15, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This study tests a combination of standard chemotherapy (bortezomib, dexamethasone), an immunotherapy (pembrolizumab), and a lab-modified virus (pelareorep) in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to see if adding the virus makes the treatment safer and more effective. About 10 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.